Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck

Company Update - Protagonist Therapeutics (NASDAQ: PTGX) is preparing to report top-line results from its phase 3 VERIFY study for rusfertide (PTG-300), a subcutaneous injectable Hepcidin Mimetic, targeting Polycythemia Vera (PV) patients [1] Author Background - The article is authored by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace [4] - Biotech Analysis Central offers a library of 600+ biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis, live chat, and analysis/news reports for healthcare investors [1] Subscription Details - Biotech Analysis Central SA marketplace subscription costs $49 per month [4] - A yearly subscription plan offers a 33.50$399 per year [4] - A two-week free trial period is currently available for new subscribers [4]